ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07), Zacks reports.
ProMIS Neurosciences Stock Performance
NASDAQ:PMN opened at $0.50 on Monday. The business’s fifty day moving average is $0.65 and its 200 day moving average is $0.84. The firm has a market cap of $16.22 million, a price-to-earnings ratio of -4.96 and a beta of 0.02. ProMIS Neurosciences has a 52-week low of $0.47 and a 52-week high of $2.37.
Wall Street Analyst Weigh In
Separately, Guggenheim reiterated a “buy” rating and issued a $6.00 target price on shares of ProMIS Neurosciences in a research note on Tuesday, April 1st.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
See Also
- Five stocks we like better than ProMIS Neurosciences
- Why Invest in High-Yield Dividend Stocks?
- Tech Bears Should Jump on These 3 Inverse ETFs
- What is a Bond Market Holiday? How to Invest and Trade
- 5 Reasons the Rebound in Microchip Technology Stock Is Real
- What Are Dividend Challengers?
- Rocket Lab: Earnings Miss But Neutron Momentum Holds
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
